DOCSLIB.ORG

( 12 ) United States Patent ( 10 ) Patent No .: US 10,946,009 B2 Li Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
( 12 ) United States Patent ( 10 ) Patent No .: US 10,946,009 B2 Li Et Al USO10946009B2 ( 12 ) United States Patent ( 10 ) Patent No .: US 10,946,009 B2 Li et al . ( 45 ) Date of Patent : Mar. 16 , 2021 ( 54 ) COMBINATION DOSAGE FORM OF A MU 7,951,400 B2 5/2011 Desai et al . OPIOID RECEPTOR ANTAGONIST AND AN 8,246,986 B2 8/2012 Cruz et al . 8,247,555 B2 8/2012 Dalziel et al . OPIOID AGENT 8,247,559 B2 8/2012 Colson et al . 8,263,618 B2 9/2012 Long et al . ( 71 ) Applicant: THERAVANCE BIOPHARMA R & D 8,476,440 B2 7/2013 Colson et al . IP , LLC , South San Francisco , CA 8,536,335 B2 9/2013 Dalziel et al . ( US ) 8,580,310 B2 11/2013 Krishnamurthy et al . 8,664,242 B2 3/2014 Long et al . 8,685,450 B2 4/2014 Lim et al. ( 72 ) Inventors : Shaoling Li , Sunnyvale, CA ( US ); 8,816,091 B2 8/2014 Dalziel et al . Manshiu Leung , Daly City, CA ( US ) ; 8,927,573 B2 1/2015 Long et al . Hao Zhang , Foster City, CA ( US ) ; 9,206,172 B2 12/2015 Long et al . Venkat R. Thalladi , Foster City, CA 9,290,491 B2 3/2016 Dalziel et al . 9,663,509 B2 5/2017 Long et al . ( US ) ; Yun Mo , Foster City, CA (US ) 9,949,963 B2 4/2018 Dalziel et al . 10,081,626 B2 9/2018 Long et al. ( 73 ) Assignee : Theravance Biopharma R & D IP , 2006/0199839 A1 9/2006 Goldblum et al . LLC , South San Francisco , CA ( US ) 2007/0219278 Al 9/2007 Long et al . 2008/0207676 Al 8/2008 Dalziel et al . Subject to any disclaimer , the term of this 2008/0269198 Al 10/2008 Benjamin et al . ( * ) Notice : 2010/0291183 Al 11/2010 Farrell et al . patent is extended or adjusted under 35 2011/0287093 Al 11/2011 Schoenhard U.S.C. 154 ( b ) by 74 days. 2012/0009227 A1 1/2012 Humar et al . 2013/0164384 A1 6/2013 Johnson et al . ( 21 ) Appl . No .: 16 / 454,353 2014/0079778 Al 3/2014 Narang et al . 2014/0271862 Al 9/2014 Jacob et al . 2018/0050028 A1 2/2018 Li et al . ( 22 ) Filed : Jun . 27 , 2019 2018/0200246 A1 7/2018 Dalziel et al . ( 65 ) Prior Publication Data 2019/0119267 A1 4/2019 Long et al . US 2019/0321350 A1 Oct. 24 , 2019 FOREIGN PATENT DOCUMENTS CN 101500542 A 8/2009 Related U.S. Application Data CN 102858324 A 1/2013 ( 62 ) Division of application No. 15 / 798,647 , filed on Oct. JP 2009-185046 A 8/2009 31 , 2017 , now Pat . No. 10,369,142 , which is a JP 2013-538814 A 10/2013 division of application No. 15 / 086,816 , filed on Mar. 31 , 2016 , now abandoned . OTHER PUBLICATIONS ( 60 ) Provisional application No. 62 / 141,981 , filed on Apr. Yao , Jing , “ Application directory of pharmaceutical excipients ” , 2 , 2015 . China Medical Science and Technology Press , pp . 37-39 ( 2011 ) . Yao , Risheng, “ Pharmaceutical polymer materials ” , Chemical Indus ( 51 ) Int . Cl . try Press, pp . 166-167 ( 2003 ). A61K 31/46 ( 2006.01 ) International Search Report for PCT / US2016 / 025176 dated Jun . 24 , A61K 31/439 ( 2006.01 ) 2016 . A61K 9/24 Koo et al . , “ Investigation into Stability of Poly ( Vinyl Alcohol ) ( 2006.01 ) Based Opadry II Films” , AAPS PharmSci Tech , 2011 , vol . 12 , No. A61K 31/485 ( 2006.01 ) 2 , pp . 746-754. A61K 9/28 ( 2006.01 ) Poster Presentation , Abstract 0520 , PAINWeek 2015 , Sep. 8-12 , ( 52 ) U.S. CI . 2015 , Las Vegas , NV . CPC A61K 31/46 ( 2013.01 ) ; A61K 9/209 Theravance Biopharma, Inc. , Investor and Analyst' Day Presenta ( 2013.01 ) ; A61K 9/282 ( 2013.01 ) ; A61K 9/284 tion , New York , NY ( Dec. 12 , 2014 ) . ( 2013.01 ) ; A61K 9/2853 ( 2013.01 ) ; A61K 9/2893 ( 2013.01 ) ; A61K 31/439 ( 2013.01 ) ; A61K 31/485 ( 2013.01 ) Primary Examiner Mina Haghighatian ( 58 ) Field of Classification Search ( 74 ) Attorney, Agent, or Firm — Jeffrey A. Hagenah ; CPC ...... A61K 31/46 ; A61K 31/439 ; A61K 9/209 ; Florence Jovic A61K 9/2893 ; A61K 9/282 ; A61K 9/2853 ; A61K 9/284 ( 57 ) ABSTRACT See application file for complete search history . The invention provides a solid composition of the peripheral ( 56 ) References Cited mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an U.S. PATENT DOCUMENTS immediate release form and an opioid analgesic agent which 6,277,384 B1 8/2001 Kaiko et al . may be in an extended release , sustained release , modified 6,451,806 B2 9/2002 Farrar release, or controlled release form and methods of preparing 7,622,508 B2 11/2009 Long et al . such a combination dosage form . 7,842,307 B2 11/2010 Oshlack et al . 7,932,402 B2 4/2011 Colson et al . 7,943,772 B2 5/2011 Dalziel et al . 14 Claims , 6 Drawing Sheets U.S. Patent Mar. 16 , 2021 Sheet 1 of 6 US 10,946,009 B2 120 80 %LABELCLAIM 60 AXELOPRAN 20 -- OXYCODONE 0 0 2 4 6 8 10 12 TIME (HR ) FIG . 1A 140 120 %LABELCLAIM AXELOPRAN 40 met een OXYCODONE 20 0 0 2 4 6 8 10 12 TIME (HR ) FIG . 1B U.S. Patent Mar. 16 , 2021 Sheet 2 of 6 US 10,946,009 B2 120 100 wwwxxx 80 %LABELCLAIM 60 ook om AXELOPRAN 40 mento forma OXYMORPHONE 20 0 0 5 15 TIME (HR ) FIG . 2A 120 100 %LABELCLAIM YYYY AXELOPRAN 40 met OXYMORPHONE 20 0 0 65 10 15 TIME (HR ) FIG . 2B U.S. Patent Mar. 16 , 2021 Sheet 3 of 6 US 10,946,009 B2 1000 Chan OXYCODONE ALONE - AXELOPRANOXYCODONE COMBINATION DOSAGE FORM PLASMACONCENTRATION(ng/mL) A AXELOPRAN + OXYCODONE OXYCODONE 10 ???? 0 20 60 80 TIME (HR ) FIG . 3A O. AXELOPRAN ALONE med 100 mem AXELOPRAN /OXYCODONE COMBINATION DOSAGE FORM PLASMACONCENTRATION(ng/mL) AXELOPRAN + OXYCODONE AXELOPRAN 10 humillaBununla * 20 40 60 TIME (HR ) FIG . 3B U.S. Patent Mar. 16 , 2021 Sheet 4 of 6 US 10,946,009 B2 10 gagangan - OXYMORPHONE ALONE - AXELOPRAN + OXYMORPHONE *** OXYMORPHONEPLASMACONCENTRATION (ng/mL) w AXELOPRANOXYMORPHONE COMBINATION DOSAGE FORM T 0 20 40 80 TIME (HR ) FIG . 4A 1000 33 -C AXELOPRAN ALONE - AXELOPRANOXYMORPHONE COMBINATION DOSAGE FORM PLASMACONCENTRATION(ng/mL) 4 AXELOPRAN + OXYMORPHONE AXELOPRAN 10 0.1 I 0.01 0 20 TIME (HR ) FIG . 4B U.S. Patent Mar. 16 , 2021 Sheet 5 of 6 US 10,946,009 B2 mua meAXELOPRANOXYCODONE COMBINATION DOSAGE FORM w we fuerans AXELOPRAN + OXYCODONE OXYCODONECONCENTRATION(ng/ml) - OXYCODONE ALONE 0 . Www 6 12 18 24 30 36 42 54 60 66 72 TIME AFTER DOSE (HR ) FIG . 5 mmmm AXELOPRAN OXYCODONE COMBINATION DOSAGE FORM 20 vef Funes AXELOPRAN + OXYCODONE - AXELOPRAN ALONE AXELOPRANCONCENTRATION(ng/mL) ??? w 0.01 0 6 12 18 24 30 36 42 48 54 60 66 72 TIME AFTER DOSE (HR ) FIG . 6 U.S. Patent Mar. 16 , 2021 Sheet 6 of 6 US 10,946,009 B2 RELATIVEINTENSITY(%) Warhammer WhenAman 0 5 ????????10 15 20 25 30 20 (DEGREES ) FIG . 7 10 8 WEIGHTCHANGE(%) 4 2 -2 8 16 24 32 ELAPSED TIME ( HR ) FIG . 8 US 10,946,009 B2 1 2 COMBINATION DOSAGE FORM OF A MU (U.S. Pat . Nos . 7,622,508 and 7,943,772 ) has been demon OPIOID RECEPTOR ANTAGONIST AND AN strated clinically to ameliorate the symptoms of OIC in OPIOID AGENT non - cancer pain patients on a stable opioid regimen without compromising analgesia . ( Vickery et al . Pain Week 2012 , CROSS - REFERENCE TO RELATED 5 Las Vegas, Nev . ( P - 87 ) . APPLICATIONS Patients taking opioid analgesics for pain management may find it useful to also take a peripheral opioid antagonist This application is a divisional of U.S. Ser. No. 15/798 , to manage adverse side effects of their pain medication . 647 , filed on Oct. 31 , 2017 , now allowed ; which is a Such patients, who may be suffering from a variety of divisional application of U.S. Ser. No. 15 / 086,816 , filed on 10 serious conditions, frequently are also prescribed additional Mar. 31 , 2016 , now abandoned ; which application claims drugs and thus are burdened with managing a complicated the benefit of U.S. Provisional Application No. 62 / 141,981 , pharmaceutical regimen . Therefore, it may be desirable to filed on Apr. 2 , 2015 the disclosure ofwhich is incorporated combine multiple drugs in a combination dosage form for herein by reference in its entirety . ease of administration and improved therapeutic compli BACKGROUND OF THE INVENTION 15 ance . In particular, use of a combination of a peripheral opioid antagonist, such as axelopran , and an opioid agonist Field of the Invention may address concerns of OIC before they develop . Depending on the clinical need , opioid analgesics can be The invention is directed to a solid composition of a administered through oral, transdermal and parenteral routes peripheral mu opioid receptor antagonist and to a combina- 20 for either chronic or acute use , of which oral administration tion of the mu opioid receptor antagonist composition and an is commonly preferred . While immediate release opioids opioid analgesic agent . In particular, the invention is directed to a unit dosage form in which the mu opioid provide efficacious pain management, especially for acute receptor antagonist is in an immediate release form and the and break - through pain , controlled or extended release opi opioid analgesic agent may be in an extended release, 25 theoids prophylactic have demonstrated effect of significant a peripheral clinical opioid value antagonist . However is, sustained release , modified release , or controlled release typically achieved by immediate release of the antagonist form and to methods of preparing such a unit dosage form.
Load more

Recommended publications
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Mai Muuttunut Piu Miu Miui
    MAIMUUTTUNUT US009943513B1 PIU MIU MIUI (12 ) United States Patent ( 10 ) Patent No. : US 9 ,943 ,513 B1 Hughey et al. (45 ) Date of Patent: * Apr . 17 , 2018 (54 ) OPIOID ABUSE DETERRENT DOSAGE (58 ) Field of Classification Search FORMS None See application file for complete search history . (71 ) Applicant : BANNER LIFE SCIENCES LLC , High Point , NC (US ) (56 ) References Cited ( 72 ) Inventors : Justin Hughey , Asheboro , NC (US ) ; U . S . PATENT DOCUMENTS Saujanya Gosangari, Jamestown, NC (US ) ; Chue Hue Yang , Greensboro , NC 4 , 828 ,836 A 5 / 1989 Miller 4 ,861 , 598 A 8 / 1989 Oshlack (US ) 4 , 970 ,075 A 11/ 1990 Oshlack 5 ,266 ,331 A 11/ 1993 Oshlack (73 ) Assignee : BANNER LIFE SCIENCES LLC , 5 , 273 , 760 A 12 / 1993 Oshlack High Point, NC (US ) 5 , 286 ,493 A 2 / 1994 Oshlack 5 ,472 , 943 A 12 / 1995 Crain 5 , 478 , 577 A 12 / 1995 Kaiko ( * ) Notice : Subject to any disclaimer, the term of this 5 , 529 , 787 A 6 / 1996 Ayer patent is extended or adjusted under 35 5 , 549 , 912 A 8 / 1996 Kaiko U . S . C . 154 ( b ) by 0 days. 5 ,656 , 295 A 8 / 1997 Oshlack 5 ,672 , 360 A 9 / 1997 Kaiko This patent is subject to a terminal dis 5 , 702 , 725 A 12 / 1997 Chadha claimer . 5 ,914 ,131 A 6 / 1999 Ayer 5 ,958 , 452 A 9 / 1999 Oshlack ( 21) Appl . No. : 15 /285 ,837 5 , 965 , 161 A 10 / 1999 Oshlack 6 , 228 , 863 B1 5 /2001 Kaiko ( 22 ) Filed : Oct . 5 , 2016 6 , 261, 599 B1 7 / 2001 Huang Related U .
    [Show full text]
  • Treatment of Opioid-Induced Constipation
    ractices Zdanowicz, Adv Practice Nurs 2016, 2:3 P in ed c N n u DOI: 10.4172/2573-0347.1000118 a r s v i n Journal of d g A ISSN: 2573-0347 Advanced Practices in Nursing Research Article Open Access Treatment of Opioid-induced Constipation: A Therapeutic Update Martin M Zdanowicz* University of Miami School of Nursing and Health Studies, 5030 Brunson Drive, Coral Gables, Florida, USA Abstract Opioids remain the most effective therapeutic agents for the management of moderate to severe pain. A significant number of patients receive long-term opioid therapy for chronic pain. While a number of opioid side effects such as sedation, nausea and vomiting, and respiratory depression diminish over time due to the development of tolerance, the constipating effects of opioid persist throughout the course of therapy. Opioid-induced constipation (OIC) is associated with marked bowel dysfunction that can significantly impact a patient’s quality of life and affect their drug adherence. A step-wise approach to treating OIC should be considered which includes life style modifications, administration of laxatives and stool-softeners, and if necessary, pharmacologic agents to enhance bowel motility and antagonize peripheral μ-opioid receptors. Although OIC is a significant adverse effect associated with opioid use, clinical studies have shown that a number of effective treatment strategies are available for both preventing OIC or reducing its severity. Keywords: Opioids; Opioid-induced constipation; μ-opioid that is characterized by abdominal pain, hard stools, fecal impaction, receptors; Laxatives anorexia, nausea and vomiting [5]. Introduction The presence of OIC can significantly impact a patient’s quality of life and can lead to dose reduction or even cessation of opioid pain In 2013, an estimated 207 million opioid prescriptions were therapy.
    [Show full text]
  • Emerging Therapies for Patients with Symptoms of Opioid-Induced Bowel Dysfunction
    Journal name: Drug Design, Development and Therapy Journal Designation: Review Year: 2015 Volume: 9 Running head verso: Leppert Drug Design, Development and Therapy Dovepress Running head recto: Emerging therapies for OIBD open access to scientific and medical research DOI: http://dx.doi.org/10.2147/DDDT.S32684 Open Access Full Text Article REVIEW Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction Wojciech Leppert Abstract: Opioid-induced bowel dysfunction (OIBD) comprises gastrointestinal (GI) symp- toms, including dry mouth, nausea, vomiting, gastric stasis, bloating, abdominal pain, and Chair and Department of Palliative Medicine, Poznan University of opioid-induced constipation, which significantly impair patients’ quality of life and may lead Medical Sciences, Poznan, Poland to undertreatment of pain. Traditional laxatives are often prescribed for OIBD symptoms, although they display limited efficacy and exert adverse effects. Other strategies include pro- kinetics and change of opioids or their administration route. However, these approaches do not address underlying causes of OIBD associated with opioid effects on mostly peripheral opioid receptors located in the GI tract. Targeted management of OIBD comprises purely peripherally acting opioid receptor antagonists and a combination of opioid receptor agonist and antagonist. Methylnaltrexone induces laxation in 50%–60% of patients with advanced diseases and OIBD who do not respond to traditional oral laxatives without inducing opioid withdrawal symptoms with similar response (45%–50%) after an oral administration of naloxegol. A combination of For personal use only. prolonged-release oxycodone with prolonged-release naloxone (OXN) in one tablet (a ratio of 2:1) provides analgesia with limited negative effect on the bowel function, as oxycodone displays high oral bioavailability and naloxone demonstrates local antagonist effect on opioid receptors in the GI tract and is totally inactivated in the liver.
    [Show full text]
  • Exploring Relief and Managing Side Effects of This Activity Issupported Byan Educationalgrant from Astrazeneca
    JOURNAL SUPPLEMENT A CME/CE Supplement to PWJ—PAINWeek Journal Exploring Relief and of Effects Side Managing RELEASE DATE: December 1, 2014 EXPIRATION DATE: December 31, 2015 Sponsored by Global Education Group. Med Learning Group is the education partner. This activity is supported by an educational grant from AstraZeneca. Faculty Program Overview Sanford M. Silverman, MD This case-based enduring activity will cover the personalized care of patients with Medical Director chronic pain. Comprehensive Pain Medicine Target Audience Pompano Beach, Florida This activity is designed to meet the educational needs of frontline clinicians who care for patients with chronic pain such as physicians, nurse practitioners, physician assistants, and pharmacists. Learning Objectives Upon completion of the program, attendees should be able to: - Discuss the different classes of analgesics used in the treatment of chronic pain, and their safety, efficacy and indications - Recognize the most common opioid-induced side effects, OIC, and the impact of treatments on analgesia - Identify attitudes, barriers and facilitators to communicating with patients about their bowel habits - Identify treatments used for the management of OIC Physician Accreditation Statement- Global Education Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Physician Credit Designation- Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nursing Continuing Education- Global Education Group is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
    [Show full text]
  • Palliation of Opioid-Induced Constipation
    7/6/2016 DEFINITIONS • Opioid-Induced Constipation (OIC) vs 2016 ANNUAL MEETING Reflux Bloating • Opioid-Induced Bowel Dysfunction (OIBD) Abdominal cramping motility Hard/dry stools PALLIATION OF OPIOID-INDUCED coordination of sphincter function Incomplete evacuation CONSTIPATION: WHAT’S NEW coordination of secretion Shelley S. Spradley, PharmD, BCPS Clinical Pharmacy Specialist: Pain Management, Palliative Care Poulsen et al. 2015. 2016 ANNUAL MEETING OBJECTIVES OIBD/OIC PREVALENCE & IMPACT • Review prevalence and impact of opioid-induced ** Lack of uniform definition, interpret with caution ** constipation (OIC) • OIC probably most well characterized adverse event in opioid-treated patients • 15-81% in patients without cancer • Discuss the available treatment options for OIC with an • Multinational, internet-based survey of 322 chronic opioid users: 81% despite use emphasis on pathophysiology of laxatives • Larger, population-based survey of 2055 pts on opioids + laxatives for chronic non- • Devise a therapeutic plan to incorporate new cancer pain: 57% prevalence of constipation pharmacologic agents for refractory constipation 1. Moore RA et al. 2005. 2. Bell TJ et al. 2009. 2016 ANNUAL MEETING 2016 ANNUAL MEETING CASE TOWARDS A CONSENSUS DEFINITION OF OIC • 46yo WF with PMH significant for stage V breast cancer, left sided malignant pleural effusion s/p PleurX catheter A change when initiating opioid therapy from baseline presenting with shortness of breath. Medicine team bowel habits that is characterized by any of the following: consult for pharmacy pain evaluation due to high dose opioid analgesics and non-formulary Relistor • Reduced bowel movement frequency • Morphine SA 300mg po q8h • Development or worsening of straining to pass bowel • Hydromorphone 16mg po q3h prn movements • Metoclopramide 10mg po tid • Docusate 100mg po bid • Sense of incomplete rectal evacuation • Senna 17.2mg po bid • Harder stool consistency • Polyethylene glycol 17grams po bid • Methylnaltrexone(Relistor) 12mg/0.6ml SubQ q48h Camilleri M et al.
    [Show full text]
  • PHARMACY and THERAPEUTICS COMMITTEE AGENDA Date Of
    STATE OF NEVADA DEPARTMENT OF HEALTH AND HUMAN SERVICES RICHARD WHITLEY, DIVISION OF HEALTH CARE FINANCING AND POLICY MS Director 1100 E. William Street, Suite 101 BRIAN SANDOVAL Carson City, Nevada 89701 MARTA JENSEN Governor (775) 684-3676 · Fax (775) 687-3893 Acting Administrator NOTICE OF PUBLIC MEETING – PHARMACY AND THERAPEUTICS COMMITTEE AGENDA Date of Posting: xxxxx Date of Meeting: Thursday, December 3, 2015 at 1:00 PM Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Pharmacy and Therapeutics Committee. Place of Meeting: JW Marriott – Las Vegas Marbella Room 221 N. Rampart Blvd Las Vegas, NV 89145 Phone: (702) 869-7777 Please check with hotel staff to verify room location A visual and audio feed will also be broadcast via the internet and phone for those who are unable to attend in person. See below for details. Webinar Pre-Registration: https://catamaranrx.webex.com/catamaranrx/onstage/g.php ?MTID=e6caebf863da965b41ca7ba5f5a4c5731 **Must Pre-Register** Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting Webinar Event: https://catamaranrx.webex.com/catamaranrx/onstage/g.php ?MTID=e6caebf863da965b41ca7ba5f5a4c5731 Event Number: 740 124 858 September 28, 2015 Page 2 Click "Join Now" Follow the instructions that appear on your screen to join the teleconference. Teleconference: 1 (855) 210-1642 Access Code: 3844816 Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Tanya Benitez at: 775-684-3722 or email [email protected] in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, DC 20549
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 2, 2014 THERAVANCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 000-30319 94-3265960 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 901 Gateway Boulevard South San Francisco, California 94080 (650) 808-6000 (Addresses, including zip code, and telephone numbers, including area code, of principal executive offices) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 7.01 Regulation FD Disclosure. The information in this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Securities Exchange Act of 1934”), or otherwise subject to the liabilities of that Section. The information in this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
    [Show full text]
  • DRUG NEWS Many Consumers Exceed Safe Dosages Breaking
    DRUG NEWS NONPRESCRIPTION NSAIDs HERBAL REMEDY Many consumers exceed Kratom isn’t “just a plant”—it’s an opioid safe dosages The botanical product kratom is used recreationally to self-medicate for pain or opioid withdrawal symptoms. Also known as Mitragyna speciosa, kratom grows An online 1-week diary study of 1,326 naturally in Thailand, Malaysia, Indonesia, and Papua New Guinea. ibuprofen users revealed that many In a statement, the FDA announced the results of research showing that almost people exceed the recommended dai- all of kratom’s major compounds bind to opioid receptors in the brain. In addition, ly limit, increasing the risk of adverse the research found that kratom binds as strongly to mu-opioid receptors as sched- reactions. Among the findings: uled opioid drugs. “As the scientific data and adverse event reports have clearly re- • About 90% of participants took vealed, compounds in kratom make it so it isn’t just a plant—it’s an opioid.” over-the-counter ibuprofen during At the time the statement was issued, the FDA had received 44 reports of death associated with kratom use. “Kratom should not be used to treat medical conditions, the week, and 37% also took other nor should it be used as an alternative to prescription opioids,” the FDA warns. “There nonsteroidal anti-inflammatory drugs is no evidence to indicate that kratom is safe or effective for any medical use.” (NSAIDs). Most didn’t realize that the Source: Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the drugs are all in the same category.
    [Show full text]
  • Peripherally Acting Mu-Opioid Antagonist for the Treatment of Opioid-Induced
    Peripherally Acting Mu-Opioid Antagonist for the Treatment of Opioid-Induced Constipation: Systematic Review and Meta-Analysis Short Title: Mu-Opioid Antagonist for OIC Kenichi Nishie1,2, Shuhei Yamamoto3, Takayoshi Yamaga4, Naoto Horigome5, Masayuki Hanaoka6 1 Department of Respiratory Medicine, Iida Municipal Hospital, 438 Yawatamachi Iida, Nagano 395-0814, Japan. E-mail: [email protected] 2 The First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, 390-8621, Japan. E-mail: [email protected] 3 Department of Rehabilitation, Shinshu University Hospital, 3-1-1 Asahi Matsumoto, 390-8621, Japan. E-mail: [email protected] 4 Department of Occupational Therapy, Health Science University, 7187 Kodachi, Fujikawaguchikomachi, Yamanashi, Japan E-mail: [email protected] 5 Department of Digestive Surgery, Iida Municipal Hospital, 438 Yawatamachi Iida, Nagano 395-0814, Japan. E-mail: [email protected] 6 The First Department of Internal Medicine, Shinshu University School of Medicine, 3-1-1 Asahi Matsumoto, 390-8621, Japan. E-mail: [email protected] *Corresponding Author: Kenichi Nishie, Department of Respiratory Medicine, Iida Municipal Hospital, 438 Yawatamachi Iida, Nagano 395-0814, Japan. E-mail: [email protected] 1 Abstract Background and Aim: Opioid-induced constipation (OIC) is a frequent adverse event (AE) that impairs patients’ quality of life (QOL). Peripherally acting mu-opioid receptor antagonists (PAMORAs) have been recognized as a treatment option for OIC but the effect consistent across the studies has not been evaluated. Methods: We conducted a quantitative meta-analysis to explore the efficacy of PAMORA for OIC (registered with PROSPERO: CRD42018085298).
    [Show full text]
  • Opioid Receptor Antagonist (Pamoras) for the Management of Patients with Opioid-Induced Constipation: a Systematic Review
    Open Access Review Article DOI: 10.7759/cureus.16201 Efficacy and Safety of Peripherally Acting μ- Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review Martina Rekatsina 1 , Antonella Paladini 2 , Asbjørn M. Drewes 3 , Farrah Ayob 4 , Omar Viswanath 5 , Ivan Urits 6 , Oscar Corli 7 , Joseph Pergolizzi Jr 8 , Giustino Varrassi 9 1. Pain Management, Whipps Cross Hospital Barts Health NHS, London, GBR 2. Department of Clinical Medicine, Public Health and Life Science (MESVA), University of L'Aquila, L'Aquila, ITA 3. Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, DNK 4. Anesthesia, Barts Health, London, GBR 5. Pain Management, Valley Pain Consultants - Envision Physician Services, Phoenix, USA 6. Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA 7. Pain and Palliative Care Research Unit, Mario Negri Institute IRCCS, Milano, ITA 8. Research Department, Nema Research, Inc., Naples, USA 9. Research, Paolo Procacci Foundation, Roma, ITA Corresponding author: Giustino Varrassi, [email protected] Abstract In treating chronic and acute pain, opioids are widely used. Although they do provide analgesia, their usage does come with adverse events (AEs). One of the most burdensome is opioid-induced bowel dysfunction, and more specifically opioid-induced constipation (OIC). The pathogenesis of these AEs is well known as the consequence of the action of opioids on m-receptors in the enteric nervous system. In recent years, medicines counteracting this specific action at the receptors have been registered for clinical use: the peripherally acting μ-opioid receptor antagonists (PAMORAs).
    [Show full text]
  • WO 2018/005695 Al O
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2018/005695 A l 0 4 January 2018 (04.01.2018) W ! P O PCT (51) International Patent Classification: (72) Inventors: BASTA, Steven; 590 Berkeley Avenue, Menlo A61K 31/4035 (2006.01) A61P 17/04 (2006.01) Park, CA 94025 (US). JOING, Mark; 936 Clara Drive, Pa A61K 45/06 (2006.01) lo Alto, CA 94303 (US). ZHANG, Xiaoming; 1089 Rem- sen Court, Sunnyvale, CA 94087 (US). KWON, Paul; 3349 (21) International Application Number: Deer Hollow Dr, Danville, CA 94506 (US). PCT/US20 17/039829 (74) Agent: SILVERMAN, Lisa, N.; Morrison & Foerster LLP, (22) International Filing Date: 755 Page Mill Road, Palo Alto, CA 94304-1018 (US). 28 June 2017 (28.06.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/356,280 29 June 2016 (29.06.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 62/356,291 29 June 2016 (29.06.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/356,301 29 June 2016 (29.06.2016) us MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 62/356,294 29 June 2016 (29.06.2016) us OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 62/356,286 29 June 2016 (29.06.2016) us SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, 62/356,271 29 June 2016 (29.06.2016) us TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]